MCID: PLG002
MIFTS: 51

Plague malady

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Plague

Aliases & Descriptions for Plague:

Name: Plague 12 56 41 3 14 69
Yersiniosis 56 3
Yersinia Infections 69

Characteristics:

Orphanet epidemiological data:

56
plague
Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 56  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:3482
ICD10 33 A20 A20.9
ICD9CM 35 020 020.9
MeSH 42 D010930
NCIt 47 C85015
Orphanet 56 ORPHA707
MESH via Orphanet 43 D010930 D015009
UMLS via Orphanet 70 C0032064 C0043407
ICD10 via Orphanet 34 A20.0 A20.1 A20.2 more
UMLS 69 C0032064

Summaries for Plague

MedlinePlus : 41 plague is an infection caused by the bacterium yersinia pestis. the bacteria are found mainly in rats and in the fleas that feed on them. people and other animals can get plague from rat or flea bites. in the past, plague destroyed entire civilizations. today plague is uncommon, due to better living conditions and antibiotics. there are three forms of plague: bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. symptoms include fever, aches, chills, and tender lymph glands. in septicemic plague, bacteria multiply in the blood. it causes fever, chills, shock, and bleeding under the skin or other organs. pneumonic plague is the most serious form. bacteria enter the lungs and cause pneumonia. people with the infection can spread this form to others. this type could be a bioterror agent. lab tests can diagnose plague. treatment is a strong antibiotic. there is no vaccine. nih: national institute of allergy and infectious diseases

MalaCards based summary : Plague, also known as yersiniosis, is related to pneumonic plague and bubonic plague, and has symptoms including fever and pruritus. An important gene associated with Plague is CCR5 (C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and African trypanosomiasis. The drugs Adjuvants, Immunologic and Aluminum phosphate have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and lymph node, and related phenotypes are cellular and cardiovascular system

Disease Ontology : 12 A primary bacterial infectious disease that results_in infection, located in lymph node, located in vasculature or located in lungs, has material basis in Yersinia pestis, which is transmitted_by oriental rat flea (Xenopsylla cheopis) infected by feeding on rodents and other mammals, transmitted_by air, transmitted_by direct contact or transmitted_by ingestion of contaminated undercooked food.

CDC : 3 Plague is a disease that affects humans and other mammals. It is caused by the bacterium, Yersinia pestis. Humans usually get plague after being bitten by a rodent flea that is carrying the plague bacterium or by handling an animal infected with plague. Plague is infamous for killing millions of people in Europe during the Middle Ages. Today, modern antibiotics are effective in treating plague. Without prompt treatment, the disease can cause serious illness or death. Presently, human plague infections continue to occur in the western United States, but significantly more cases occur in parts of Africa and Asia.

Related Diseases for Plague

Diseases related to Plague via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Related Disease Score Top Affiliating Genes
1 pneumonic plague 12.5
2 bubonic plague 12.4
3 septicemic plague 12.3
4 pestis minor 11.4
5 tularemia 11.2
6 smallpox 11.1
7 anthrax disease 10.8
8 variola major 10.8
9 variola minor 10.8
10 polyarteritis nodosa 10.2 CD86 MYD88
11 primary polycythemia 10.1 CCR5 CTSC
12 pustulosis palmaris et plantaris 10.1 PECAM1 TYMP
13 lymph node disease 10.0 PECAM1 SELE
14 tuberculosis 10.0
15 hemiplegic migraine 10.0 PECAM1 PLG
16 common variable immunodeficiency 9.9 PLG TYMP
17 cholera 9.9
18 ecthyma 9.8
19 typhoid fever 9.8
20 pneumonia 9.8
21 influenza 9.8
22 malaria 9.7
23 relapsing fever 9.7
24 measles 9.7
25 hiv-1 9.6
26 leprosy 9.6
27 keratitis 9.6
28 hemochromatosis 9.6
29 scurvy 9.6
30 crohn's disease 9.6
31 hepatitis 9.6
32 laryngotracheitis 9.6
33 swine influenza 9.6
34 mucositis 9.6
35 thrombotic thrombocytopenic purpura 9.6
36 q fever 9.6
37 bartonellosis 9.6
38 dysentery 9.6
39 blastomycosis 9.6
40 scrub typhus 9.6
41 schistosomiasis 9.6
42 hantavirus pulmonary syndrome 9.6
43 leptospirosis 9.6
44 vaccinia 9.6
45 purpura 9.6
46 mouth disease 9.6
47 mediastinitis 9.6
48 pellagra 9.6
49 leishmaniasis 9.6
50 transmitted_by 9.6

Graphical network of the top 20 diseases related to Plague:



Diseases related to Plague

Symptoms & Phenotypes for Plague

UMLS symptoms related to Plague:


fever, pruritus

MGI Mouse Phenotypes related to Plague:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 MGAT1 MYD88 PECAM1 PLG SELE TYMP
2 cardiovascular system MP:0005385 10.06 CCR5 INVS MGAT1 MYD88 PECAM1 PLG
3 digestive/alimentary MP:0005381 10.01 CCR5 CDC25C DDX58 INVS MYD88 PECAM1
4 growth/size/body region MP:0005378 9.97 PLG PTS SELE CDC25C CTSC DDX58
5 hematopoietic system MP:0005397 9.96 DDX58 INVS MGAT1 MYD88 PECAM1 PLG
6 homeostasis/metabolism MP:0005376 9.93 CCR5 CD86 CTSC DDX58 INVS MGAT1
7 endocrine/exocrine gland MP:0005379 9.91 CD86 CDC25C INVS MGAT1 MYD88 PLG
8 immune system MP:0005387 9.65 CCR5 CD86 CTSC DDX58 INVS MYD88
9 liver/biliary system MP:0005370 9.1 CCR5 DDX58 INVS PECAM1 PLG SELE

Drugs & Therapeutics for Plague

Drugs for Plague (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1
2 Aluminum phosphate Phase 4
3 Antacids Phase 4,Phase 1
4 Anti-Ulcer Agents Phase 4,Phase 1
5 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
6 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
7 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
8 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2
9 Calcium, Dietary Phase 4,Phase 3
10 Anticholesteremic Agents Phase 4
11 Hypolipidemic Agents Phase 4
12 Lipid Regulating Agents Phase 4
13 Rosuvastatin Calcium Phase 4 147098-20-2
14
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
15
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
16
Etanercept Approved, Investigational Phase 3 185243-69-0
17
Morphine Approved, Investigational Phase 3 57-27-2 5288826
18
Interferon beta-1a Approved, Investigational Phase 3 145258-61-3 6438354
19
Crizotinib Approved Phase 3,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
20
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
21
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
22
Cytarabine Approved, Investigational Phase 3,Early Phase 1 147-94-4 6253
23
Etoposide Approved Phase 3,Phase 1,Phase 2,Early Phase 1 33419-42-0 36462
24
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
25
Methotrexate Approved Phase 3,Phase 2,Early Phase 1 1959-05-2, 59-05-2 126941
26
Hydrocortisone Approved, Vet_approved Phase 2, Phase 3 50-23-7 5754 657311
27
Budesonide Approved Phase 3 51333-22-3 63006 5281004
28
Rivaroxaban Approved Phase 3 366789-02-8
29
rituximab Approved Phase 3 174722-31-7 10201696
30
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
31
Idarubicin Approved Phase 3 58957-92-9 42890
32
Lenograstim Approved Phase 3 135968-09-1
33
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
34
Vedolizumab Approved Phase 3 943609-66-3
35
Ustekinumab Approved, Investigational Phase 3 815610-63-0
36
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
37
Pregabalin Approved, Illicit, Investigational Phase 3 148553-50-8 5486971
38
Adalimumab Approved Phase 3 331731-18-1 16219006
39
Dimethyl fumarate Approved, Investigational Phase 3 624-49-7 637568 5271565
40
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
41
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
42
Ofloxacin Approved Phase 3 82419-36-1 4583
43
Xylometazoline Approved Phase 3 526-36-3 5709
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Early Phase 1 59-30-3 6037
45
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Early Phase 1 58-05-9 54575, 6560146 143
46 tannic acid Approved, Nutraceutical Phase 3
47
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265
48
Butyric Acid Experimental Phase 2, Phase 3 107-92-6 264
49 Anti-Bacterial Agents Phase 2, Phase 3
50 Anti-Infective Agents Phase 2, Phase 3, Early Phase 1

Interventional clinical trials:

(show top 50) (show all 97)
id Name Status NCT ID Phase
1 Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons Completed NCT01404182 Phase 4
2 Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years Completed NCT01424228 Phase 4
3 School Inner-City Asthma Intervention Study (SICAS-2) Recruiting NCT02291302 Phase 4
4 EASY: Extended Access to Sollpura Over Years Recruiting NCT02823964 Phase 4
5 Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging Not yet recruiting NCT02041117 Phase 4
6 Treatment and Diagnosis of Plague Completed NCT00128466 Phase 2, Phase 3
7 Mouse Allergen and Asthma Intervention Trial Completed NCT01251224 Phase 3
8 A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension Completed NCT00644605 Phase 3
9 SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis Completed NCT02279498 Phase 3
10 Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy Completed NCT00676507 Phase 3
11 Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects Completed NCT02378506 Phase 3
12 Phase 3 Study of RPC1063 in Relapsing MS Completed NCT02294058 Phase 3
13 Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study) Completed NCT02047734 Phase 3
14 Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™ Completed NCT00445185 Phase 3
15 A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B. Completed NCT00291941 Phase 3
16 An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Completed NCT00932893 Phase 3
17 Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns Recruiting NCT02700828 Phase 2, Phase 3
18 Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) Recruiting NCT02465567 Phase 3
19 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Recruiting NCT02111564 Phase 3
20 Study to Assess if ABP798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Rituximab Recruiting NCT02792699 Phase 3
21 (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive Recruiting NCT02039726 Phase 3
22 A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Recruiting NCT03114657 Phase 3
23 Vedolizumab Subcutaneous Long-Term Open-Label Extension Study Recruiting NCT02620046 Phase 3
24 Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease Recruiting NCT02611817 Phase 3
25 A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis Recruiting NCT02576717 Phase 3
26 A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis Recruiting NCT02438787 Phase 3
27 A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations Recruiting NCT02413580 Phase 3
28 An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis Recruiting NCT02407223 Phase 3
29 Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 Recruiting NCT02403323 Phase 3
30 A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease Recruiting NCT02394028 Phase 3
31 A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02165215 Phase 3
32 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Recruiting NCT02118584 Phase 3
33 A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02100696 Phase 3
34 Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) Recruiting NCT02239120 Phase 3
35 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures. Recruiting NCT01747915 Phase 3
36 A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) Recruiting NCT02706951 Phase 3
37 A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate Recruiting NCT02706873 Phase 3
38 A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate Recruiting NCT02629159 Phase 3
39 A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clon Recruiting NCT01463306 Phase 3
40 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) Recruiting NCT02907177 Phase 3
41 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis Active, not recruiting NCT02611830 Phase 3
42 Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis Active, not recruiting NCT01583374 Phase 3
43 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) Active, not recruiting NCT01307423 Phase 3
44 PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Active, not recruiting NCT01212757 Phase 3
45 Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections Active, not recruiting NCT01978938 Phase 3
46 A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) Not yet recruiting NCT03162796 Phase 3
47 VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome Terminated NCT01130246 Phase 3
48 A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Terminated NCT01798485 Phase 3
49 The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects Terminated NCT01975389 Phase 3
50 The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects Terminated NCT01975376 Phase 3

Search NIH Clinical Center for Plague

Genetic Tests for Plague

Anatomical Context for Plague

MalaCards organs/tissues related to Plague:

39
Lung, Testes, Lymph Node, Spleen, Skin, Thymus, Tonsil

The Foundational Model of Anatomy Ontology organs/tissues related to Plague:

18
Lymph Node, Vasculature Or

Publications for Plague

Articles related to Plague:

(show top 50) (show all 864)
id Title Authors Year
1
Effects of substrate salinity on oviposition, embryonic development and survival in the Australian plague locust, Chortoicetes terminifera (Walker). ( 27742224 )
2017
2
Yersinia pestis halotolerance illuminates plague reservoirs. ( 28054667 )
2017
3
Plenty Is No Plague: Streptomyces Symbiosis with Crops. ( 27916552 )
2017
4
Characterization of duck plague virus stability at extreme conditions of temperature, pH and salt concentration. ( 27746073 )
2017
5
Epidemiological analysis of the Eyam plague outbreak of 1665-1666. ( 27170724 )
2016
6
New Insights into Autoinducer-2 Signaling as a Virulence Regulator in a Mouse Model of Pneumonic Plague. ( 27981238 )
2016
7
Adjunctive Corticosteroid Treatment Against Yersinia pestis Improves Bacterial Clearance, Immunopathology, and Survival in the Mouse Model of Bubonic Plague. ( 27402776 )
2016
8
Oral vaccination against plague using Yersinia pseudotuberculosis. ( 27046452 )
2016
9
Neither plague nor malaria, but dysentery as a cause of death for St. Louis. ( 26759133 )
2016
10
Classic Spotlight: Studies on the Low-Calcium Response of Yersinia pestis Reveal the Secrets of Plague Pathogenesis. ( 27413177 )
2016
11
Notes from the Field: Plague in Domestic Cats - Idaho, 2016. ( 27932783 )
2016
12
Plazomicin is effective in a non-human primate pneumonic plague model. ( 27614915 )
2016
13
Correction: Temporal Progression of Pneumonic Plague in Blood of Nonhuman Primate: A Transcriptomic Analysis. ( 27078634 )
2016
14
Drug Testing and Toxicology: Redefining the Plague of Darkness. ( 27842795 )
2016
15
Outbreak of Plague in a High Malaria Endemic Region - Nyimba District, Zambia, March-May 2015. ( 27513350 )
2016
16
Modeling of spatio-temporal variation in plague incidence in Madagascar from 1980 to 2007. ( 27839576 )
2016
17
Cross-Species Antiviral Activity of Goose Interferons against Duck Plague Virus Is Related to Its Positive Self-Feedback Regulation and Subsequent Interferon Stimulated Genes Induction. ( 27438848 )
2016
18
Plague in Arab Maghreb, 1940-2015: A Review. ( 27376053 )
2016
19
Plague Vaccine Development: Current Research and Future Trends. ( 28018363 )
2016
20
Spatial analysis and identification of high risk plague regions in Pakistan based on associated rodent species distribution. ( 27482799 )
2016
21
Assessment of Live Plague Vaccine Candidates. ( 27076149 )
2016
22
Immunogenicity and Safety of Subunit Plague Vaccine: A Randomized Phase 2a Clinical Trial. ( 27159397 )
2016
23
Molecular history of plague. ( 27615720 )
2016
24
Plague Doctors in the HIV/AIDS Epidemic: Mental Health Professionals and the "San Francisco Model," 1981-1990. ( 27374849 )
2016
25
Temporal Progression of Pneumonic Plague in Blood of Nonhuman Primate: A Transcriptomic Analysis. ( 27003632 )
2016
26
Enteric Fever: A Slow Response to an Old Plague. ( 27171237 )
2016
27
Genetic variation at the MHC DRB1 locus is similar across Gunnison's prairie dog (Cynomys gunnisoni) colonies regardless of plague history. ( 27066243 )
2016
28
Characterization of the Funeral Groups Associated with Plague Epidemics. ( 27726769 )
2016
29
Highly Effective Soluble and Bacteriophage T4 Nanoparticle Plague Vaccines Against Yersinia pestis. ( 27076150 )
2016
30
Crayfish plague Aphanomyces astaci detected in redclaw crayfish, Cherax quadricarinatus in Taiwan. ( 27039156 )
2016
31
Molecular, serological and epidemiological observations after a suspected outbreak of plague in Nyimba, eastern Zambia. ( 27578859 )
2016
32
Hong Kong Junk: Plague and the Economy of Chinese Things. ( 27040025 )
2016
33
The Continuing Plague of Extended-spectrum I^-lactamase-producing Enterobacteriaceae Infections. ( 27208763 )
2016
34
Boils-A Modern Take on the Plague of Egypt. ( 27627038 )
2016
35
A Plague of Rats. ( 27199410 )
2016
36
Possible links between white plague-like disease, scleractinian corals, and a cryptochirid gall crab. ( 28000605 )
2016
37
A Deadly Path: Bacterial Spread During Bubonic Plague. ( 26875618 )
2016
38
Plague in China 2014-All sporadic case report of pneumonic plague. ( 26895880 )
2016
39
Host transcriptomic responses to pneumonic plague reveal that Yersinia pestis inhibits both the initial adaptive and innate immune responses in mice. ( 27876297 )
2016
40
Evaluation of Yersinia pestis Transmission Pathways for Sylvatic Plague in Prairie Dog Populations in the Western U.S. ( 27234457 )
2016
41
Ecological Opportunity, Evolution, and the Emergence of Flea-borne Plague. ( 27160296 )
2016
42
From plague to MERS: coordinating Australia's response to emerging infectious diseases. ( 27997933 )
2016
43
A replication-defective human type-5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and non-human primates. ( 27170642 )
2016
44
Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague. ( 27060051 )
2016
45
Xenopsylla brasiliensis Fleas in Plague Focus Areas, Madagascar. ( 27513742 )
2016
46
Pathogenicity of duck plague and innate immune responses of the Cherry Valley ducks to duck plague virus. ( 27553496 )
2016
47
Normal growth, altered growth? Study of the relationship between harris lines and bone form within a post-medieval plague cemetery (Dendermonde, Belgium, 16th Century). ( 27338787 )
2016
48
SEASON OF DELTAMETHRIN APPLICATION AFFECTS FLEA AND PLAGUE CONTROL IN WHITE-TAILED PRAIRIE DOG (CYNOMYS LEUCURUS) COLONIES, COLORADO, USA. ( 27195680 )
2016
49
Historical Y.A pestis Genomes Reveal the European Black Death as the Source of Ancient and Modern Plague Pandemics. ( 27281573 )
2016
50
Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague. ( 27745954 )
2016

Variations for Plague

Expression for Plague

Search GEO for disease gene expression data for Plague.

Pathways for Plague

Pathways related to Plague according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.29 CD86 PECAM1 SELE
2 10.7 MYD88 SELE
3 10.49 MYD88 PECAM1 SELE

GO Terms for Plague

Biological processes related to Plague according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.33 CD86 MYD88 SELE
2 response to interleukin-1 GO:0070555 8.96 MYD88 SELE
3 viral process GO:0016032 8.92 CCR5 CD86 CDC25C DDX58

Molecular functions related to Plague according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 coreceptor activity GO:0015026 8.62 CCR5 CD86

Sources for Plague

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....